期刊名称：MECHANISMS OF DEVELOPMENT
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Mechanisms of Development
|
Mechanisms of Development is an international journal whose purpose is to communicate contemporary studies in developmental biology with special emphasis on the characterization of molecular mechanisms underlying development processes in either vertebrates, invertebrates or plants. Areas of particular interest include embryogenesis, pattern formation, cell determination and differentiation, specification of tissue type, targetted disruptions of developmental control genes, the roles of transcription factor in development, regulatory hierarchies of gene expression, cell-cell communication and signal transduction in development, as well as post-transcriptional controls of developmental processes such as regulated splicing and protein modification. |
|
Such a focus should provide a unique forum for comparing and contrasting strategies of development among a wide spectrum of organisms. The Editors are strongly committed to establishing the highest standards of quality and scientific merit, and guarantee rapid communication of important contributions.
Abstracting and Indexing
- BIOBASE
- BIOSIS
- Biological & Agricultural Index
- Biological Abstracts
- Biosis Previews
- Chemical Abstracts
- Current Awareness in Biological Sciences
- Current Contents/Life Sciences
|
|
- EMBASE
- EMBiology
- Genetics Abstracts
- MEDLINE®
- Pascal et Francis (INST-CNRS)
- Science Citation Index
- Scopus
|
Instructions to Authors
Mechanisms of Development is an international journal whose purpose is to communicate contemporary studies in developmental biology with special emphasis on the characterization of molecular mechanisms underlying development processes in either vertebrates or invertebrates. Areas of particular interest include embryogenesis, pattern formation, cell determination and differentiation, specification of tissue type, targetted disruptions of developmental control genes, the roles of transcription factor in development, regulatory hierarchies of gene expression, cell-cell communication and signal transduction in development, as well as post-transcriptional controls of developmental processes such as regulated splicing and protein modification.
Such a focus should provide a unique forum for comparing and contrasting strategies of development among a wide spectrum of organisms. The Editors are strongly committed to establishing the highest standards of quality and scientific merit, and guarantee rapid communication of important contributions.
Types of paper
The journal will publish full-length articles describing original, high quality research and occasional invited Reviews.
(Please note that Gene Expression Patterns are published in a separate sister journal, Gene Expression Patterns:  http://www.elsevier.com/locate/gep.)
Flow charts to help authors decide whether papers are suitable for Mechanisms of Development or Gene Expression Patterns are available HERE.
Contact details for submission
Manuscripts for Mechanisms of Development should be submitted via the journal's online submission system at http://ees.elsevier.com/mod/.
For questions on the submission and reviewing process, please contact mod@elsevier.com or one of the handling Editors.
For technical questions, please use our help site at: http://epsupport.elsevier.com/. Here you will be able to learn more about the online submission and editorial system via interactive tutorials, explore a range of problem solutions via our knowledgebase, and find answers to frequently asked questions. You will also find our support contact details should you need any assistance from one of our customer service representatives.
Page charges
This journal has no page charges.
Ethics in Publishing
For information on Ethics in Publishing and Ethical guidelines for journal publication see http://www.elsevier.com/publishingethics and http://www.elsevier.com/ethicalguidelines.
Policy and ethics
The work described in your article must have been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans http://www.wma.net/e/policy/b3.htm; EC Directive 86/609/EEC for animal experiments http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm; Uniform Requirements for manuscripts submitted to Biomedical journals http://www.icmje.org. This must be stated at an appropriate point in the article.
Conflict of interest
All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also http://www.elsevier.com/conflictsofinterest.
Submission declaration
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.
Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright see http://www.elsevier.com/copyright). Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult http://www.elsevier.com/permissions). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult http://www.elsevier.com/permissions.
Retained author rights
As an author you (or your employer or institution) retain certain rights; for details you are referred to: http://www.elsevier.com/authorsrights.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. If the funding source(s) had no such involvement then this should be stated. Please see http://www.elsevier.com/funding.
Funding body agreements and policies
Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies.
Language and language services
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who require information about language editing and copyediting services pre- and post-submission please visit http://www.elsevier.com/languageediting or our customer support site at http://epsupport.elsevier.com for more information.
Submission
Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.
When invited to do so by the handling editor after the review process, authors are normally expected to submit a revised version within about 6 months.
Referees
Please submit, with the manuscript, the names, addresses and e-mail addresses of 3 potential referees. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.
Suggested referees must not be from your own institution and must not have collaborated with you at least during the last five years, and should not already have provided you with comments on the manuscript. You may also suggest up to two referees to exclude due to conflicts of interest.
Additional information
Publication of a research article in Mechanisms of Development implies that the authors agree to distribute all non-commercially obtained materials used in the experiments (e.g. cells, DNA, antibodies, primary data) to other academic researchers for their own use, including verification. All nucleic acid and protein sequences must have been deposited in the appropriate databases and the Accession Numbers cited in the final version of the manuscript.
For each and every accession number cited in an article, Authors should type the accession number in bold, underlined text . Letters in the accession number should always be capitalised. This combination of letters and format will enable Elsevier's typesetters to recognise the relevant texts as accession numbers and add the required link to GenBank's sequences.
Data from microarray and other similar screens
Please see the MGED open letter specifying microarray standards at http://www.mged.org/Workgroups/MIAME/miame_checklist.html. Authors submitting manuscripts relying on microarray or similar screens must supply the data as Supplementary data (see below) at the time of submission, along with the completed MIAME checklist. The data must be MIAME-compliant and supplied in a form that is widely accessible. The microarray data must also be submitted to either the GEO ( http://www.ncbi.nlm.nih.gov/geo/ or ArrayExpress ( http://www.ebi.ac.uk/arrayexpress/ databases, with accession numbers at or before acceptance of the paper for publication.
The Editors understand that on occasion authors may not feel it appropriate to deposit the entire data set at the time of publication of this paper. We are therefore willing to consider exceptions to this requirement in response to a request from the authors, which must be made at the time of initial submission or as part of an informal pre-submission enquiry.
Mouse gene expression data
Upon acceptance of the manuscript for publication, authors reporting mouse gene expression data from RNA in situ hybridization, immunohistochemistry, Northern blot, Western blot and RT-PCR experiments are requested to submit the pertinent data to the Mouse Gene Expression Database (GXD). These submissions will receive accession numbers that must then be inserted into the manuscript. Please see GXD's guidelines for electronic data submission at http://www.informatics.jax.org/mgihome//GXD/GEN/gxd_submission_guidelines.shtml.
Use of wordprocessing software
It is important that the file be saved in the native format of the wordprocessor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the wordprocessor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. Do not embed "graphically designed" equations or tables, but prepare these using the wordprocessor's facility. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: http://www.elsevier.com/guidepublication). Do not import the figures into the text file but, instead, indicate their approximate locations directly in the electronic text and on the manuscript. See also the section on Electronic illustrations.
To avoid unnecessary errors you are strongly advised to use the "spell-check" and "grammar-check" functions of your wordprocessor.
However, be aware that neither of these is infallible and you are therefore strongly encouraged to seek the opinion of a native English-speaking, scientifically trained colleague.
Please use 1.5 line spacing and either Arial or Times Roman font, at least 11 point size.
Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to "the text". Any subsection may be given a brief heading. Each heading should appear on its own separate line.
Subdivision – numbered sections
Divide your article into clearly defined and numbered sections. Normally the Introduction should be Section 1., followed by Results (Section 2), then Discussion (Section 3) and Experimental Procedures (Section 4). Acknowledgements and References should follow but not be numbered. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to "the text", "above", etc.. Any subsection may be given a brief heading. Each heading should appear on its own separate line.
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.
Introduction
State the objectives of the work and provide an adequate but concise background. Explain why the study was undertaken and how it is timely and/or novel.
Experimental
Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.
Results
Results should be clear and concise.
Results
The Results section should be written objectively, free from interpretation. It should be clear and concise.
Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.
Discussion
This should explore the significance of the results of the work, not repeat the Results section. It is generally appropriate to use this section to relate the results to other published work and to explain how they differ, or their novelty, as well as how they advance the field. However, it should also be concise and avoid extensive reference to other work in the authors laboratory unless directly relevant to this study. It may be useful to end the Discussion with a very brief Conclusions sub-section of a single paragraph.
Experimental Procedures
Provide sufficient detail to allow the experiments and results to be reproduced. Methods already published should be indicated by references to publications where the details may be found: only relevant departures from published methods should be described.
Theory / calculations / statistical analysis
Where appropriate, a theoretical, mathematical or statistical analysis section may be included. This should not repeat any material within the rest of the article. If the analysis of the results includes complex statistical or other mathematical analysis, this should be detailed in this section, which may be a sub-section of the Experimental Procedures or follow it (as Section 5).
Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on.
Appendices
These should be avoided unless absolutely essential. If there is a theoretical or mathematical section and this needs to be substantial then it may be better to inlude it as an Appendix which may be included in the printed paper or as on-line Supplementary or Supporting Material, at the Handling Editor's discretion. If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: (Eq. A.1), (Eq. A.2), etc.; in a subsequent appendix, (Eq. B.1) and so forth.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
• Author names and affiliations. Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name, and, if available, the e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that telephone and fax numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address.
• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a "Present address" (or "Permanent address") may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Abstract
A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).
The nomenclature should be the same as adopted by the major cell/developmental biology journals (e.g., Cell, Developmental Cell, The EMBO Journal).
Footnotes
Footnotes are not allowed.
e-CRC
General points: Elsevier can only accept MS Word, LaTeX, or postscript/PDF documents as electronic camera-ready copy (e-CRC). Electronic files can be stored on CD or may be transferred to Elsevier via FTP (details available from Customer support: http://epsupport.elsevier.com).
MS Word file: Please ensure that you use normal fonts as much as possible in your documents, such as Times New Roman, Arial, Symbol, Helvetica, or Times (TrueType or Type 1 fonts). Special fonts, such as those used in the Far East (Japanese, Chinese, Korean, etc.) may be cause problems during processing. If you use a lot of special fonts, please convert the document to PDF with Adobe Acrobat (see below, and also Elsevier's Quickguide: http://www.elsevier.com/wps/find/authorsview.authors/howtosubmitpaper). Please place figures in a logical place within the document (see also the section on Preparation of electronic illustrations at http://www.elsevier.com/artworkinstructions). To avoid unnecessary errors you are strongly advised to use the "spellchecker" function of your wordprocessor.
LaTeX documents: Please use a LaTeX setup that uses Type 1 fonts instead of the sometimes default bitmap fonts (Type 3, or pk fonts). For instance, using the LaTeX Times package may be enough to enable this adjustment. For information on LaTex see http://www.elsevier.com/latex. Please provide all document-related and temporary files on submission, as well as the resulting postscript or PDF file.
Postscript/PDF files: Please create postscript files, making sure all fonts are embedded. When creating PDF files with Adobe Acrobat, please use version 4.05 or higher, and use the standard "Press Optimized" settings, as provided by Adobe.
Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Save text in illustrations as "graphics" or enclose the font.
• Only use the following fonts in your illustrations: Arial, Courier, Times, Symbol.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Produce images near to the desired size of the printed version.
• Submit each figure as a separate file.
A detailed guide on electronic artwork is available on our website:
http://www.elsevier.com/artworkinstructions
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless of the application used, when your electronic artwork is finalised, please "save as" or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS: Vector drawings. Embed the font or save the text as "graphics".
TIFF: color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF: Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF: Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.
DOC, XLS or PPT: If your electronic artwork is created in any of these Microsoft Office applications please supply "as is".
Please do not:
• Supply embedded graphics in your wordprocessor (spreadsheet, presentation) document;
• Supply files that are optimised for screen use (like GIF, BMP, PICT, WPG); the resolution is too low;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
The figures should ideally be 1000 dpi (min. 300dpi).
The figures may be in either RGB or CMYK format. If supplying in RGB format, please check the typeset proof carefully to ensure the color is an accurate representation of the original figure.
The figures should be the correct size so that no reduction or enlargement has to be carried out. If this is not possible it is better if the figures are sent 'too large' so that details will not be lost in the reduction process.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) in addition to color reproduction in print. For further information on the preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
Figure Legends
Ensure that each illustration has a Legend. Supply legends separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a brief description of the illustration including all panels. Keep text in the illustrations themselves to a minimum while endeavoring that they can be understood with minimal reference to the legend.
Tables
Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either "Unpublished results" or "Personal communication" Citation of a reference as "in press" implies that the item has been accepted for publication.
Citations in Text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not allowed in the reference list,and strongly discouraged in the text. If such references are absolutely essential in the text, evidence must be provided at the time of submission (by an explicit statement in the covering letter or "manuscript details" during submission) that the source of the "personal communication" agrees to these data being mentioned by the authors in this paper. Citation of a reference as "in press" implies that the item has been accepted for publication.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.
Web References
References to personal or institutional web sites are not allowed. Any references to Web sites must be restricted to on-line resources (such as NLM, GXD, Zfin, EBI, Ensembl, Genbank, etc.) that are likely to be permanent. The full URL should be given. Web references should not be included in the reference list but must be embedded in the text.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.
Reference style
Text: All citations in the text should refer to:
1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;
2. Two authors: both authors' names and the year of publication;
3. Three or more authors: first author's name followed by "et al." and the year of publication.
Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.
Examples: "as demonstrated (Allan, 1996a, 1996b, 1999; Allan and Jones, 1995). Kramer et al. (2000) have recently shown ...."
List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters "a", "b", "c", etc., placed after the year of publication.
Examples:
Reference to a journal publication:
Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2000. The art of writing a scientific article. J. Sci. Commun. 163, 51–59.
Reference to a book:
Strunk Jr., W., White, E.B., 1979. The Elements of Style, third ed. Macmillan, New York.
Reference to a chapter in an edited book:
Mettam, G.R., Adams, L.B., 1999. How to prepare an electronic version of your article, in: Jones, B.S., Smith , R.Z. (Eds.), Introduction to the Electronic Age. E-Publishing Inc., New York, pp. 281–304.
Journal abbreviations source
Journal names should be abbreviated according to
Index Medicus journal abbreviations: http://www.nlm.nih.gov/tsd/serials/lji.html;
List of serial title word abbreviations: http://www.issn.org/2-22661-LTWA-online.php;
CAS (Chemical Abstracts Service): http://www.cas.org/sent.html.
Video data
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a maximum size of 10 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.
Supplementary data
Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions.
Supplementary Material
MOD accepts electronic supplementary material to support and enhance your published paper. Supplementary files offer the author additional possibilities to publish supporting applications, movies, animation sequences, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com/. In order to ensure that your submitted material is directly usable, please ensure that data are provided in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. Video files: please supply a 'still' with each of your files: you can choose any frame from the video or make a separate image. These will be used instead of standard icons and will personalize the link to your supplementary information. For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions.
Submission checklist
It is hoped that this list will be useful during the final checking of an article prior to sending it to the journal's Editor for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following items are present:
One Author designated as corresponding Author:
• E-mail address
• Full postal address
• Telephone and fax numbers
All necessary files have been uploaded
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been "spellchecked" and "grammar-checked"
• References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Web)
• Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print or to be reproduced in color on the Web (free of charge) and in black-and-white in print
• If only color on the Web is required, black and white versions of the figures are also supplied for printing purposes
For any further information please visit our customer support site at http://epsupport.elsevier.com.
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. The correct format for citing a DOI is shown as follows (example taken from a document in the journal Physics Letters B):
doi:10.1016/j.physletb.2003.10.071
When you use the DOI to create URL hyperlinks to documents on the web, they are guaranteed never to change.
Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or higher) available free from http://www.adobe.com/products/acrobat/readstep2.html. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: http://www.adobe.com/products/acrobat/acrrsystemreqs.html#70win.
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.
Offprints
The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.
For inquiries relating to the submission of articles (including electronic submission where available) please visit this journal's homepage. You can track accepted articles at http://www.elsevier.com/trackarticle and set up e-mail alerts to inform you of when an article's status has changed. Also accessible from here is information on copyright, frequently asked questions and more. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher.
Editorial Board
Editor-in-Chief
D. Wilkinson
Division of Developmental Neurobiology, The National Institute for Medical Research, The Ridgeway, Mill Hill, London, NW7 1AA, UK, Fax: +4420 8816 2523, Tel: +4420 8816 2404, Email: modgep@nimr.mrc.ac.uk
Editors:
C Klaembt
Institut für Neurobiologie, Badestr. 9, D-48149 Münster, Germany, Fax: +49-251-832-4686, Tel: +49-251-832-1122, Email: klaembt@uni-muenster.de
Y. Saga
Div. of Mammalian Development, National Institute of Genetics, Yata 1111, 411-8540 Mishima, Japan, Fax: +81-55-981-6828, Tel: +81-55-981-6829, Email: ysaga@lab.nig.ac.jp
D. Stainier
Dept. of Biochemistry & Biophysics, University of California at San Francisco (UCSF), San Francisco, CA 94143, USA, Fax: +1 415 476 3892, Tel: +1 415 502 5679, Email: didier.stainier@ucsf.edu
Editorial Board:
K. Agata
Kyoto University, Kyoto, Japan
H.-H. Arnold
Technische Universität Carola-Wilhelmina zu Braunschweig, Braunschweig, Germany
S. Artavanis-Tsakonas
Harvard Medical School, Boston, MA, USA
Y. Barde
Universität Basel, Basel, Switzerland
K. Basler
Universität Zürich, Zürich, Switzerland
M. Bienz
Medical Research Council (MRC), Cambridge, UK
E. Boncinelli
International School for Advanced Studies, Trieste, Italy
A.H. Brivanlou
Rockefeller University, New York, USA
M. Bronner-Fraser
California Institute of Technology, Pasadena, CA, USA
S.A. Camper
University of Michigan Medical School, Ann Arbor, MI, USA
M.R. Capecchi
University of Utah School of Medicine, Salt Lake City, UT, USA
M. Chalfie
Columbia University, New York, NY, USA
W. Chia
National University of Singapore (NUS), Singapore, Singapore
S. Cohen
National University of Singapore (NUS), Singapore, Singapore
E.H. Davidson
California Institute of Technology, Pasadena, CA, USA
E.M. DeRobertis
University of California at Los Angeles (UCLA), Los Angeles, CA, USA
F. Dieterlen-Lièvre
Centre National de la Recherche Scientifique (CNRS), Nogent sur Marne, France
W. Driever
Albert-Ludwigs-Universität Freiburg, Freiburg, Germany
D. Duboule
Université de Genève, Geneva 4, Switzerland
S. Dunwoodie
Victor Chang Cardiac Research Institute, Sydney, NSW, Australia
G. Eichele
Baylor College of Medicine, Houston, TX, USA
R.A. Firtel
University of California, San Diego (UCSD), La Jolla, CA, USA
W.W. Franke
Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
M. Freeman
Medical Research Council (MRC), Cambridge, UK
W. Gehring
Universität Basel, Basel, Switzerland
A. Grapin-Botton
Swiss Institute for Experimental Cancer Research, Epalinges/Lausanne, Switzerland
F. Gros
Institut Pasteur, Paris Cedex 15, France
E. Hafen
Eidgenössische Technische Hochschule Zürich (ETH), Zürich, Switzerland
M.E. Halpern
Carnegie Institution of Washington, Baltimore, MD, USA
J.K. Heath
Ludwig Institute For Cancer Research, Parkville, VIC, Australia
M. Hibi
Institute for Physical and Chemical Research, Chuoh-ku, Kobe, Japan
O. Hobert
Columbia University, New York, NY, USA
P.W. Ingham
Agency for Science, Technology and Research (A*STAR), Proteos, Singapore
J.C. Izpisúa Belmonte
The Salk Institute for Biological Studies, La Jolla, CA, USA
H. Jäckle
Max Planck Institut (MPI) für Biophysikalische Chemie, Göttingen, Germany
T.M. Jessell
Columbia University Medical Center, New York, NY, USA
S. Jesuthasan
National University of Singapore (NUS), Singapore, Singapore
T.C. Kaufman
Indiana University, Bloomington, IN, USA
M. Kessel
Max Planck Institut (MPI) für Biophysikalische Chemie, Göttingen, Germany
J. Kimble
University of Wisconsin at Madison, Madison, WI, USA
A. Kispert
Medizinische Hochschule Hannover, Hannover, Germany
W. Knöchel
Universität Ulm, Ulm, Germany
H. Kondoh
Osaka University, Osaka, Japan
P. Koopman
University of Queensland, St Lucia, QLD, Australia
M. Krasnow
Stanford University School of Medicine, Stanford, CA, USA
R. Krumlauf
Stowers Institute for Medical Research, Kansas City, MO, USA
N. Le Douarin
Centre National de la Recherche Scientifique (CNRS), Gif sur Yvette, France
A. Lumsden
King's College London, London, UK
S. Martinez
Instituto de Neurociencias de Alicante, San Juan de Alicante, Spain
A. Martinez Arias
University of Cambridge, Cambridge, UK
D.R. McClay
Duke University, Durham, NC, USA
C.B. Moens
University of Washington, Seattle, WA, USA
G. Morata
Universidad Autónoma de Madrid, Madrid, Spain
W. Nellen
Universität Gesamthochschule Kassel, Kassel, Germany
C. Niehrs
Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
M.A. Nieto
Instituto de Neurociencias de Alicante, San Juan de Alicante, Spain
L. Niswander
University of Colorado Health Sciences Center, Aurora, CO, USA
P. O'Farrell
University of California at San Francisco (UCSF), San Francisco, CA, USA
G. Oliver
St. Jude Children's Research Hospital, Memphis, TN, USA
R. Paro
Eidgenössische Technische Hochschule Zürich (ETH), Basel, Switzerland
N. Perrimon
Harvard Medical School, Boston, MA, USA
T. Pieler
Georg-August Universität Göttingen, Göttingen, Germany
O. Pourquié
Stowers Institute for Medical Research, Kansas City, MO, USA
R. Renkawitz Pohl
Universität Marburg, Marburg, Germany
F.H. Ruddle
Yale University, New Haven, CT, USA
A. Ruiz i Altaba
Université de Genève, Centre Medical Universitaire (CMU), Geneva 4, Switzerland
N. Satoh
Okinawa Inst. Of Science & Tech., Okinawa, Japan
A. Schier
Harvard University, Cambridge, MA, USA
M.M. Shen
Columbia University, New York, NY, USA
J.M.W. Slack
University of Minnesota, Minneapolis, MN, USA
S.Y. Sokol
Mount Sinai School of Medicine, New York, NY, USA
D. Solter
Max Planck Institut (MPI) für Immunobiologie, Freiburg, Germany
P. Sternberg
California Institute of Technology, Pasadena, CA, USA
A. Streit
King's College London, London, UK
G. Struhl
New York, NY, USA
Y. Takahashi
National Institute of Advanced Industrial Science and Technology (AIST), Ikoma, Nara, Japan
H. Takeda
University of Tokyo, Bunkyo-Ku, Japan
M. Takeichi
Riken University Japan, Kobe, Japan
N. Ueno
National Institute for Basic Biology (NIBB), Okazaki, Japan
E.F. Wagner
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
K. Weber
Max Planck Institut (MPI) für Biophysikalische Chemie, Göttingen, Germany
D. Weigel
Max Planck Institut (MPI) für Entwicklungsbiologie, Tübingen, Germany
H. Westphal
National Institute of Child Health and Human Development (NICHD), Bethesda, MD, USA
L. Willmitzer
Institut fur Genbiologische, Berlin 33, Germany
C.S. Zuker
University of California, San Diego (UCSD), La Jolla, CA, USA
|
